The FDA Authorized Test for TFR Initiation and Monitoring

The MRDx® BCR-ABL Test is a companion diagnostic for Chronic Myeloid Leukemia (CML) patients in the chronic phase (CP) being treated with Tasigna®* who may be candidates for treatment discontinuation and monitoring of treatment-free remission (TFR). Read our Press Release.

Monitoring of TFR requires the ability to accurately measure BCR-ABL transcripts to a depth, classified as MR4.5 (BCR-ABL/ABL ≤0.0032% International Scale).

The MRDx BCR-ABL Test has consistently demonstrated sensitivity in ENESTfreedom and ENESTop clinical studies to MR4.5. The MRDx BCR-ABL Test is based on real-time quantitative PCR and measures BCR-ABL transcripts (e13a2/b2a2 and/or e14a2/b3a2) from peripheral blood specimens in CML-CP Ph+ patients.

MRDx® BCR-ABL Test Brochure


The MRDx BCR-ABL Kit as well as Test can be ordered directly through MolecularMD. Additional reference laboratories will offer the test once it gets established within their systems.

MRDx® BCR-ABL Test Quantitation Services Brochure

Physician Test Report for MRDx® Test Results (sample)

MRDx® BCR-ABL Test Requisition Form

Specimen Preparation and Shipping Instructions


Contact Us

Phone: 1-866-GET-MRDX (438-6739)



*Tasigna is a registered trademark of Novartis AG